Olmesartan Medoxomil/Amlodipine Teva (Olmesartan Medoxomil, Amlodipine)

Olmesartan Medoxil/Amlodipine Teva is used in the management of high blood pressure, a condition that involves the renin‑angiotensin system and vascular tone.

• Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient.
• Hypertension with concomitant edema: adds vasodilation to reduce fluid retention.
• Hypertensive patients at cardiovascular risk: improves overall blood pressure control to reduce long‑term risk.
• Resistant hypertension: provides a dual mechanism that may aid patients not controlled on single agents.
• Hypertension in older adults: offers a once‑daily regimen that simplifies therapy.
• Hypertension with metabolic syndrome: combines an ARB and a calcium‑channel blocker without affecting glucose metabolism.

• Olmesartan medoxil blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. Together, they reduce peripheral resistance and lower blood pressure through complementary actions on the renin‑angiotensin system and calcium‑mediated vascular tone.

Olmesartan Medoxil/Amlodipine Teva may cause a range of adverse reactions. Monitoring and reporting are recommended.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness: especially after standing quickly.
• Flushing: transient warmth sensation.
• Fatigue: general tiredness.
• Nausea: occasional upset stomach.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of face, lips or throat.
• Severe hypotension: symptomatic low blood pressure.
• Hepatic dysfunction: elevated liver enzymes.
• Renal impairment: worsening kidney function.
• Myocardial infarction: rare but reported in high‑risk patients.
• Hyperkalemia: elevated potassium levels.

Before starting Olmesartan Medoxil/Amlodipine Teva, patients should be evaluated for several safety considerations.

• Renal function: assess baseline creatinine and eGFR.
• Hepatic function: check liver enzymes in patients with liver disease.
• Electrolytes: monitor potassium, especially if on potassium‑sparing diuretics.
• Pregnancy: avoid use; drug is contraindicated in the second and third trimesters.
• Elderly patients: start at lower dose and monitor for hypotension.
• Drug interactions: review concomitant medications for potential additive effects.
• Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxil/Amlodipine Teva can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade: avoid concurrent ACE inhibitors or other ARBs.
• Strong CYP3A4 inhibitors: may increase amlodipine levels (e.g., ketoconazole).

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate hypotensive effect.
• Potassium‑rich supplements or salts: risk of hyper‑kalemia.
• NSAIDs: can blunt antihypertensive response and affect renal function.
• Lithium: increased lithium levels, requiring serum monitoring.
• Simvastatin: amlodipine can raise statin concentrations, increasing myopathy risk.